Astal Laboratories Limited

BSE: ASTALLTD · Pharmaceuticals · sector

₹65.96BSE close 2026-10-26

Key numbers

Market cap₹160 cr

Price₹65.96

52w high / low₹102 / ₹60

P/E7.5xSector median 27.9x

P/B0.5xSector median 2.9x

Book value₹137.9

Dividend yield–Sector median 0.48%

ROE11.9%Sector median 11.7%

ROCE7.4%Sector median 12.3%

OPM9.2%Sector median 14.0%

Debt / equity0.15xSector median 0.16x

EV/EBITDA7.0xSector median 18.6x

Interest cover9.7x

Current ratio1.48x

Sales growth 3y+317.2%Sector median +9.6%

Profit growth 3y+802.6%Sector median +13.3%

PEG0.01x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1 cr vs borrowings ₹49 cr (FY26): borrowings are higher by ₹48 cr.
Operating profit covered interest 9.7x in the last 12 months.
Other income was 1% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹65.96 on 2026-10-26: -35.3% from the 52-week high, +9.1% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹113.00 · low ₹62.84

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	23	25	38	52	134	101
EBITDA	4	3	4	4	10	12
OPM %	17.8%	12.5%	10.3%	6.8%	7.6%	12.1%
Other income	0	0	0	0	0	0
Net profit	3	2	3	2	8	9
EPS (₹)	2.80	2.12	2.40	2.19	2.04	2.19
Revenue YoY					+471.2%	+298.5%
Profit YoY					+180.3%	+350.7%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	–	3	24	64	249	325
EBITDA	-0	-0	1	13	21	30
Net profit	-0	0	1	9	15	22
EPS (₹)	-0.04	0.04	1.55	9.08	8.62	8.82
Revenue growth		–	+589.5%	+171.6%	+287.9%	–
Profit growth		–	+3,850.0%	+1,030.4%	+64.7%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+317.2%	–	–
Net profit	+802.7%	–	–
EPS	+499.5%	–	–
Share price	–	-8.9% (2y)	-32.4%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	36	334
Borrowings	13	49
Cash & equivalents	2	1
Total assets	63	518
Fixed assets	11	64
Capital work in progress	0	–
Investments	0	0
Receivables	28	156
Inventory	15	68
Payables	11	124

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	-13	-18
Cash from investing	-8	-2
Cash from financing	3	3
Capex	6	1
Free cash flow	-18	-19

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	24.8%	4.4%
ROCE %	25.7%	5.2%
Debtor days	157	229
Inventory days	112	113
Payable days	82	206
Cash conversion cycle (days)	187	136
Working capital days	107	116

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
ASTALLTD	₹160 cr	7.5x	0.5x	11.9%	7.4%	9.2%	+317.2%	–

All 185 companies in Pharmaceuticals →

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	ASTALLTD
BSE code	512600
ISIN	INE307N01014
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.